Amneal Pharmaceuticals launches its first product in spray form

BRIDGEWATER, N.J. — Amneal Pharmaceuticals launched mometasone furoate nasal spray, the company's first pharmaceutical product in spray form. 

Mometasone furoate, available in 50 mcg/spray strength, is an AB-rated therapeutic equivalent to Nasonex. Amneal's generic comes packaged in a white, high-density, polyethylene bottle fitted with a white, metered-dose, manual spray pump and turquoise cap. Each 17-gram bottle delivers 120 sprays.

"This launch marks a new milestone for us," said Jim Luce, Amneal’s EVP Sales and Marketing. "As the first nasal spray product from Amneal, it stands as yet another example of how we continue to expand into new and more complex dosage forms. Metered dose inhalers, transdermal patches and chewable tablets are just a few of those in the pipeline that we are excited to bring to market, significantly expanding our product offering."

Annual U.S. sales of brand and generic Nasonex were $653 million according to December 2016 IMS market data.